Chimeric antigen receptor
A chimeric antigen receptor (CAR) is a genetically engineered receptor that confers a new antigen specificity on an immune effector cell.
A chimeric antigen receptor (CAR) is a genetically engineered receptor that confers a new antigen specificity on an immune effector cell. CARs are synthetic membrane proteins assembled from antibody-derived and T-cell signaling elements. Unlike a conventional T-cell receptor (TCR), which recognizes peptide antigens presented by major histocompatibility complex molecules, a CAR generally binds a surface antigen directly through an antibody-derived recognition domain, commonly a single-chain variable fragment (scFv).
A typical CAR contains an extracellular antigen-binding domain, a hinge or spacer region, a transmembrane segment, and one or more intracellular signaling domains. Engagement of the target antigen brings signaling components together and can activate the engineered cell, promoting cytotoxicity, cytokine production, proliferation, and persistence. CARs are most extensively used in CAR-T cells, in which T-lymphocytes are genetically modified ex vivo and reinfused as a form of CAR-T cells. The approach has also been adapted to other immune cells, including natural-killer-cell-like systems and neutrophils.
CAR-based therapies are being investigated across hematological malignancies and solid tumors. Their potential advantages include antigen-directed recognition that is less dependent on peptide presentation and the ability to combine tumor specificity with selected intracellular activation and costimulatory signals. Important biological and clinical considerations include tumor heterogeneity, antigen loss, limited trafficking or persistence in solid tumors, and immune-mediated toxicities such as cytokine release syndrome. CAR designs and delivery systems are also being studied in combination with checkpoint inhibitors, bispecific engagers, and approaches intended to overcome an immunosuppressive microenvironment.
Where the papers sit
26 papers from the last 6 months study chimeric antigen receptor directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 3 observational · 6 human data · 14 preclinical · 3 unclassified
Themes 4 themes · 1 paradigm shift · 1 new direction
-
CAR-T Engineering and Outcomes
CAR-T development is moving toward site-specific, multiplex, and drug-controllable engineering to improve persistence, tumor infiltration, and antitumor activity. Dual-target designs, adaptive 4-1BB signaling, and allo-CAR-T products aim to overcome exhaustion and antigen escape. Clinical work continues to weigh efficacy against neurotoxicity, cardiovascular events, and second primary malignancies, with microbiome effects and cell expansion emerging as potential outcome modifiers.
12 papers · 46.2%
-
CAR Therapies for Solid Tumors
Solid-tumor CAR therapy is expanding beyond conventional CAR-T cells to engineered NK cells, progenitor-derived products, and in vivo lipid-nanoparticle delivery. Synovial sarcoma studies support NKG2D targeting, while trogocytosis remains a mechanism of CAR-NK dysfunction that must be controlled. Meditope switches and estrogen-receptor-based degradation add reversible control over activity, addressing persistence and safety as well as tumor killing.
7 papers · 26.9%
-
CAR-T Therapy Optimization
CD19 antigen loss and low antigen density are emerging as major causes of CAR-T escape in large B-cell lymphoma. Glofitamab is being used as urgent bridging therapy for high-risk relapsed disease, while cytokine release syndrome remains a key risk to predict and manage. Base editing points toward multiplex-engineered immune cells, but its clinical role remains less defined.
4 papers · 15.4%
-
CAR Immune Cell Engineering
Spleen-targeted mRNA delivery is pushing CAR generation toward transient, programmable in vivo engineering rather than conventional manufacturing. T-cell-activating carriers may combine delivery and immune stimulation, while γδ T-cell pretreatment with venetoclax seeks stronger antileukemic activity ex vivo. The shared direction is simpler, more flexible immune-cell programming, although the delivery and pharmacologic approaches remain at different stages.
3 papers · 11.5%
CAR immune cells can be generated systemically in vivo rather than manufactured ex vivo
The ligand-directed lipid-nanoparticle study of CAR natural killer cells in mice, autoimmune hepatitis, and humanized hematologic malignancy models, and the polymer-lipid nanoparticle study of fibroblast-activation-protein CAR T cells for pathological-fibroblast elimination, separately show that systemic mRNA delivery can generate functional CAR cells inside the body 42870042Oct 42587055Aug. The assumed dependence on preparing CAR cells outside the patient is therefore replaced by an in vivo engineering model, in which targeted or intrinsically T-cell-activating nanoparticles provide the CAR program directly and produce therapeutic cells at the disease site or in circulation.
CARs can serve as an autonomous quality-control system that purges dysfunctional cells during manufacturing
The anti-uPAR CAR study in genetically edited primary human T-cell products uses activated, dysfunctional T cells as the target rather than tumor or pathogenic cells in the patient 42237538Jun. Strong stimulation causes a subset of product cells to express uPAR, allowing the CAR to direct fratricide within the culture, enrich the desired population, and promote its expansion. This assigns CARs a new manufacturing role as cell-intrinsic selection and purification circuitry, rather than solely as receptors for therapeutic targeting after infusion.
Papers
The 26 papers from the last 6 months that study chimeric antigen receptor directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
CAR-T Engineering and Outcomes (12)
- Brain-sensing synNotch-CAR T cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical models. Science translational medicine · 28 Oct 2026 PMID 42950017
- Sequential CD2/CD3/CD28 activation improves nonviral large-payload chimeric antigen receptor knock-in at the T cell receptor α constant locus. Cytotherapy · 1 Sept 2026 PMID 42679594
- Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression. Blood · 29 Jul 2026 PMID 42523019
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies. Cancer cell · 27 Jul 2026 PMID 42508408
- Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer. Cancer research · 23 Jul 2026 PMID 42489524
- The Gut Microbiome Drives Endogenous T-cell Activation Following CAR T-cell Therapy. Cancer immunology research · 22 Jul 2026 PMID 42485357
- Repurposing base editors for targeted knockin and simultaneous multiplex knockouts to generate allo-CAR T cells with minimal translocations. Molecular therapy : the journal of the American Society of Gene Therapy · 21 Jul 2026 PMID 42478045
- Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma. Blood · 8 Jul 2026 PMID 42418682
- Development of super Vδ2 T cells for relapsed/refractory acute myeloid Leukemia via non-viral site-specific integration. International immunopharmacology · 12 Jun 2026 PMID 42284763
- Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 12 Jun 2026 PMID 42283723
- Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells. Molecular therapy : the journal of the American Society of Gene Therapy · 4 Jun 2026 PMID 42237538
- Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries. European heart journal · 27 May 2026 PMID 42199067
CAR Therapies for Solid Tumors (7)
- Pharmacological ON/OFF Regulation of CAR T Cells through Estrogen Receptor-Based Stabilization and Targeted Degradation. ACS chemical biology · 27 Oct 2026 PMID 42945362
- In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles. Nature biotechnology · 13 Oct 2026 PMID 42870042
- Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting. Journal of hematology & oncology · 8 Oct 2026 PMID 42844630
- Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells. Cancer immunology research · 4 Aug 2026 PMID 42550958
- Depletion of an immature cord blood NK subset reverses trogocytosis-driven CAR NK dysfunction. Cancer cell · 29 Jul 2026 PMID 42526444
- Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy. Cell · 19 Jun 2026 PMID 42320470
- NKG2D-based CAR-T cells for synovial sarcoma: A preclinical proof-of-concept study. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 8 Jun 2026 PMID 42259140
CAR-T Therapy Optimization (4)
- CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after All. Blood cancer discovery · 12 Oct 2026 PMID 42862024
- Accelerated Glofitamab as Urgent Bridging to CAR T-Cell Therapy in High-Risk Relapsed/Refractory Large B-Cell Lymphoma. Hematological oncology · 11 Oct 2026 PMID 42859877
- Predicting prevalence and severity of cytokine release syndrome after CAR T-cell therapy in patients with autoimmune disease: a retrospective cohort study. The Lancet. Rheumatology · 25 Sept 2026 PMID 42790438
- A singular base-editing platform for polyfunctional multiplex engineering of immune cells. Molecular therapy : the journal of the American Society of Gene Therapy · 18 Jul 2026 PMID 42470099
CAR Immune Cell Engineering (3)
- Programmable ternary polyplexes redirect systemic mRNA delivery to the spleen for in vivo CAR engineering. Journal of controlled release : official journal of the Controlled Release Society · 21 Sept 2026 PMID 42767377
- An inherent T cell-activating mRNA delivery carrier for in vivo CAR T generation. Nature materials · 12 Aug 2026 PMID 42587055
- Ex vivo pretreatment with venetoclax boosts antileukemic efficacy of therapeutic γδ T cells in AML models. The Journal of clinical investigation · 23 Jul 2026 PMID 42490148
By study type
Observational studies and case reports (3)
- Accelerated Glofitamab as Urgent Bridging to CAR T-Cell Therapy in High-Risk Relapsed/Refractory Large B-Cell Lymphoma. Hematological oncology · 11 Oct 2026 PMID 42859877
- Predicting prevalence and severity of cytokine release syndrome after CAR T-cell therapy in patients with autoimmune disease: a retrospective cohort study. The Lancet. Rheumatology · 25 Sept 2026 PMID 42790438
- Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries. European heart journal · 27 May 2026 PMID 42199067
Human data, design not indexed (6)
- CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after All. Blood cancer discovery · 12 Oct 2026 PMID 42862024
- Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting. Journal of hematology & oncology · 8 Oct 2026 PMID 42844630
- A singular base-editing platform for polyfunctional multiplex engineering of immune cells. Molecular therapy : the journal of the American Society of Gene Therapy · 18 Jul 2026 PMID 42470099
- Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma. Blood · 8 Jul 2026 PMID 42418682
- Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 12 Jun 2026 PMID 42283723
- Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells. Molecular therapy : the journal of the American Society of Gene Therapy · 4 Jun 2026 PMID 42237538
Preclinical: animal, cell and lab studies (14)
- Brain-sensing synNotch-CAR T cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical models. Science translational medicine · 28 Oct 2026 PMID 42950017
- Programmable ternary polyplexes redirect systemic mRNA delivery to the spleen for in vivo CAR engineering. Journal of controlled release : official journal of the Controlled Release Society · 21 Sept 2026 PMID 42767377
- Sequential CD2/CD3/CD28 activation improves nonviral large-payload chimeric antigen receptor knock-in at the T cell receptor α constant locus. Cytotherapy · 1 Sept 2026 PMID 42679594
- Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells. Cancer immunology research · 4 Aug 2026 PMID 42550958
- Depletion of an immature cord blood NK subset reverses trogocytosis-driven CAR NK dysfunction. Cancer cell · 29 Jul 2026 PMID 42526444
- Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression. Blood · 29 Jul 2026 PMID 42523019
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies. Cancer cell · 27 Jul 2026 PMID 42508408
- Ex vivo pretreatment with venetoclax boosts antileukemic efficacy of therapeutic γδ T cells in AML models. The Journal of clinical investigation · 23 Jul 2026 PMID 42490148
- Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer. Cancer research · 23 Jul 2026 PMID 42489524
- The Gut Microbiome Drives Endogenous T-cell Activation Following CAR T-cell Therapy. Cancer immunology research · 22 Jul 2026 PMID 42485357
- Repurposing base editors for targeted knockin and simultaneous multiplex knockouts to generate allo-CAR T cells with minimal translocations. Molecular therapy : the journal of the American Society of Gene Therapy · 21 Jul 2026 PMID 42478045
- Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy. Cell · 19 Jun 2026 PMID 42320470
- Development of super Vδ2 T cells for relapsed/refractory acute myeloid Leukemia via non-viral site-specific integration. International immunopharmacology · 12 Jun 2026 PMID 42284763
- NKG2D-based CAR-T cells for synovial sarcoma: A preclinical proof-of-concept study. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 8 Jun 2026 PMID 42259140
Unclassified: not yet indexed with MeSH (3)
- Pharmacological ON/OFF Regulation of CAR T Cells through Estrogen Receptor-Based Stabilization and Targeted Degradation. ACS chemical biology · 27 Oct 2026 PMID 42945362
- In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles. Nature biotechnology · 13 Oct 2026 PMID 42870042
- An inherent T cell-activating mRNA delivery carrier for in vivo CAR T generation. Nature materials · 12 Aug 2026 PMID 42587055
Written from 26 PubMed abstracts, each one listed by PMID above. Published: 2026-08-20. Drafted by language models from published abstracts; not medical advice.